• Vol. 44 No. 10, 415–420
  • 15 October 2015

Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer

ABSTRACT

Introduction: The SCAN genitourinary cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer (MIBC).

Materials and Methods: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting.

Results: Three international guidelines were evaluated—those developed by the National Comprehensive Cancer Network (2014), the European Society of Medical Oncology (2011) and the European Association of Urology (2013). Recommendations on the use of neoadjuvant and adjuvant chemotherapy in MIBC were developed.

Conclusion: These adapted guidelines form the SCAN Guidelines 2015 for neoadjuvant and adjuvant chemotherapy in MIBC


In Singapore, bladder cancer is the ninth most common cancer in men. It is less frequent among women. A total of 675 new cases of bladder cancer were diagnosed between 2003 and 2007, with an estimated male to female ratio of 3:1.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.